v3.26.1
Revenue Recognition
 6 Months Ended
Jun. 30, 2026
Revenue Recognition [Abstract]  
REVENUE RECOGNITION

NOTE 3 – REVENUE RECOGNITION

 

The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product to a customer or as services are performed. Revenue is measured based on the consideration the Company receives in exchange for those products

 

The following table presents the Company’s revenue by product category for the six months ended June 30, 2026, and 2025:

 

    For the Six Months Ended
June 30,		  
    2026     2025  
Training   $ 2,067,593     $ 279,885  
Product supplies     3,370,258       1,030,089  
Equipment     3,500       8,435  
Patient procedures     1,220,766       1,029,451  
Total revenue   $ 6,662,116     $ 2,347,859  

 

Listed below are the revenue, cost of revenue, gross profit, assets and net profit (loss) by Company and its subsidiary, Global Stem Cells Group, for the six months ended June 30, 2026:

 

    For the Six Months Ended  
    June 30, 2026  
    Global Stem
Cells Group		     Regenerative
Medical
Technology
Group		     Total  
Revenue   $ 6,662,116     $ -     $ 6,662,116  
Cost of revenue     2,317,454       -       2,317,454  
Gross profit   $ 4,344,662     $ -     $ 4,344,662  
Gross Profit %     65.21 %     0.00 %     65.21 %
                         
Assets   $ 4,008,924     $ 1,841,079     $ 5,850,003  
Net profit (loss)   $ 621,595     $ (3,837,520 )   $ (3,215,926 )